Coronary Heart Disease and Chronic Heart Failure
Conditions
Interventions
Combination Therapy Group:Standard therapy plus: Kuanxiong aerosol (sublingual spray, 2 puffs each time, hold for about 30 seconds before swallowing, twice daily)
Acupuncture moxibustion (gentle moxibustion at Zhongwan, bilateral Xinshu, bilateral Neiguan, and Guanyuan acupoints, 15 minutes per point, 5 times per week, continuous for 8 weeks)
Kuanxiong Aerosol Group:Standard therapy plus: Kuanxiong aerosol (sublingual spray, 2 puffs each time, hold for about 30 seconds before swallowing, twice daily)
Sham moxibustion (using inert tools resembling moxa with similar appearance and warmth, identical procedure to real moxibustion group)
Control Group:Standard therapy plus: Sham Kuanxiong aerosol (without nitroglycerin or any herbal active ingredients, identical packaging to Kuanxiong aerosol)
Sham moxibustion treatment (same frequency and duration as previous)
Sponsors
The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. It meets the diagnostic criteria for chronic heart failure caused by coronary heart disease and is classified as grade II-III by the New York Heart Association of the United States. 2. Age: 40-75 years old, gender not limited; 3. All subjects were informed and voluntarily signed the written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with severe liver, kidney, hematopoietic system or other serious primary diseases, or tumors, and an expected lifespan of less than one year; 2. Patients with critical cardiac emergencies such as acute myocardial infarction, unstable angina pectoris, and malignant arrhythmias (such as persistent ventricular tachycardia and ventricular fibrillation); 3. Pregnant or lactating women; 4. Those who are known to be allergic to or have an allergic constitution to the ingredients of wide-chest aerosol or moxibustion; 5. Those who have participated in other clinical trials within the past month, or are currently using other drugs or therapies that may interfere with the judgment of the efficacy and safety of this study; 6. There are cognitive or mental disorders that prevent effective communication, or poor compliance, making it difficult to cooperate in completing the established treatment plan and follow-up visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left Ventricular Ejection Fraction (LVEF);N-terminal pro-B-type Natriuretic Peptide (NT-proBNP); | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-Minute Walk Distance;Minnesota Living with Heart Failure Questionnaire Score;Frequency of Angina Attacks and Nitroglycerin Use;New York Heart Association Functional Classification;Traditional Chinese Medicine Syndrome Score (symptoms related to Qi deficiency and blood stasis); | — |
Countries
China
Contacts
Public ContactLiu Xiqi
The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine
Outcome results
None listed